Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Financial Post ·
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL-15 signalling Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease TORONTO and HOUSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) — Medicenna […]
About CD122 Read More